Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Metabolism: Clinical and Experimental

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.METABOL.2007.08.017PMID 18078871
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Repetitive Fluctuations in Blood Glucose Enhance Monocyte Adhesion to the Endothelium of Rat Thoracic Aorta

  2006cited by this paper
• Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.

  2006cited by this paper
• Review: The role of insulin resistance in nonalcoholic fatty liver disease.

  2006cited by this paper
• Favorable Effects of Early Insulin Secretion by Nateglinide on Postprandial Hyperlipidemia in Patients With Type 2 Diabetes K.S. has received grant/research support from Yamanouchi Pharma.

  2006cited by this paper
• A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.

  2006cited by this paper
• The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults

  2006cited by this paper
• Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes.

  2005cited by this paper
• Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes.

  2005cited by this paper
• Is Adiponectin Involved in the Pathogenesis of Nonalcoholic Steatohepatitis?: A Preliminary Human Study

  2005cited by this paper
• Dietary fat content modifies liver fat in overweight nondiabetic subjects.

  2005cited by this paper
• Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity.

  2005cited by this paper
• Adiponectin as a protective factor in hepatic steatosis.

  2005cited by this paper
• Role of early insulin secretion in postglucose‐loading hyperglycaemia and postfat‐loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats

  2004cited by this paper
• Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test

  2004cited by this paper
• Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes

  2004cited by this paper
• A placebo‐controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes

  2004cited by this paper
• Reduced expression of peroxisome proliferator‐activated receptor‐α may have an important role in the development of non‐alcoholic fatty liver disease

  2004cited by this paper
• Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism

  2004cited by this paper
• PKClambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity.

  2003cited by this paper
• Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP‐1 suppression

  2003cited by this paper
• Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance.

  2003cited by this paper
• Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.

  2002cited by this paper
• Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes.

  2002cited by this paper
• Defect in Peroxisome Proliferator-activated Receptor α-inducible Fatty Acid Oxidation Determines the Severity of Hepatic Steatosis in Response to Fasting*

  2000cited by this paper
• Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

  2000cited by this paper
• Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.

  2000cited by this paper
• Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes.

  1999cited by this paper
• Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (−)‐N‐(trans‐4‐isopropylcyclohexane‐carbonyl)‐d‐phenylalanine (A‐4166)

  1997cited by this paper
• Development of diabetes in the non-obese NIDDM rat (GK rat).

  1988cited by this paper
• A simple method for the isolation and purification of total lipides from animal tissues.

  1957cited by this paper

• Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

  2024cites this paper
• Guidelines on models of diabetic heart disease

  2022cites this paper
• Structural lesions and changing pattern of expression of genes encoding cardiac muscle proteins are associated with ventricular myocyte dysfunction in type 2 diabetic Goto–Kakizaki rats fed a high‐fat diet

  2011cites this paper
• Nateglinide stimulates glucagon-like peptide-1 release by human intestinal L cells via a K(ATP) channel-independent mechanism.

  2011cites this paper
• Diabetes und Fettleber

  2009cites this paper
• Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice.

  2009cites this paper
• Review: Treatment options for nonalcoholic fatty liver disease

  2008cites this paper